---
title: "Regulatory Update: Serbia"
description: Serbia Regulatory Update October 2023
image: https://blog.arazygroup.com/hubfs/imgpsh_fullsize_anim-Oct-12-2023-07-58-09-2825-PM.jpg
---

Open main menu Close main menu

- [Join The Regulatory Rockstar Movement](https://info.arazygroup.com/regulatory_rockstar_movement)

[Regulatory Update](https://blog.arazygroup.com/regulatory-affairs-advance/tag/regulatory-update)

# Regulatory Update: Serbia

[Arazy Group](https://blog.arazygroup.com/regulatory-affairs-advance/author/arazy-group)

[Share this blog post on Twitter](https://twitter.com/intent/tweet?text=I+found+this+interesting+blog+post&url=https://blog.arazygroup.com/regulatory-affairs-advance/regulatory-update-serbia) [Share this blog post on Facebook](http://www.facebook.com/share.php?u=https://blog.arazygroup.com/regulatory-affairs-advance/regulatory-update-serbia) [Share this blog post on LinkedIn](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.arazygroup.com/regulatory-affairs-advance/regulatory-update-serbia)

![](https://blog.arazygroup.com/hubfs/imgpsh_fullsize_anim-Oct-12-2023-07-58-09-2825-PM.jpg)

On June 8, 2023, the Serbian Food and Drug Agency (ALIMS) introduced an Important Notice regarding reporting in the ALIMS information system for the Surveillance System for medical devices on the Market.

This notice outlines two types of reporting that are now required:

1) Post-Market Surveillance Report (PMSR): This reporting applies to Class I medical devices (except Is, Im, Ir) and Class A or other IVDs. Manufacturers are expected to update the post-marketing monitoring report (PMSR) as necessary and submit it to the Agency upon request.

2) Periodic Safety Update Report (PSUR): For medical devices falling under Is, Im, Ir, IIa, IIb, III, AIMD categories and IVDs in List A, List B, self-testing, class B, class C, and class D, periodic safety update reports (PSUR) must be maintained. The update frequency varies, with some categories requiring submissions at least once every two years while others are due annually.

In addition, there is a new deadline for reporting in the "Surveillance System for Medical Devices on the Market," which can be found [here](https://www.alims.gov.rs/2023/06/08/vazno-obavestenje-u-vezi-izvestavanja-u-informacionom-sistemu-alims-u-sistemu-pracenja-medicinskih-sredstava-na-trzistu-surveillance-za-proizvodjace-medicinskih-sredstava-u-rs-i-ovlascene-predst/)with the FULL resource. Cyrillic and English translations are available. 

 

Subscribe for more regulatory updates to stay informed!

 

## Related Articles

[![](https://blog.arazygroup.com/hubfs/iStock-1394397658.jpg)](https://blog.arazygroup.com/regulatory-affairs-advance/market-access-readiness-simplified)

[Regulatory Affairs](https://blog.arazygroup.com/regulatory-affairs-advance/tag/regulatory-affairs) [Medtech](https://blog.arazygroup.com/regulatory-affairs-advance/tag/medtech)

### [Market Access Readiness - Simplified!](https://blog.arazygroup.com/regulatory-affairs-advance/market-access-readiness-simplified)

Based on their current documentation, are you curious about how ready your medical and IVD devices are to enter new markets? Look no further than MARI%™ – the Market...

[Benjamin Arazy](https://blog.arazygroup.com/regulatory-affairs-advance/author/benjamin-arazy) 

[Read More](https://blog.arazygroup.com/regulatory-affairs-advance/market-access-readiness-simplified)

[![](https://blog.arazygroup.com/hubfs/iStock-1448474068-1.jpg)](https://blog.arazygroup.com/regulatory-affairs-advance/clinical-evaluation-reports)

[Regulatory Affairs](https://blog.arazygroup.com/regulatory-affairs-advance/tag/regulatory-affairs) [Clinical Evalutation](https://blog.arazygroup.com/regulatory-affairs-advance/tag/clinical-evalutation)

### [Clinical Evaluation Reports](https://blog.arazygroup.com/regulatory-affairs-advance/clinical-evaluation-reports)

Clinical evaluation of a medical device aims to show that the device offers more benefits and poses less risk than state-of-the-art treatments or is at least comparable...

[Diana Gavrilov Negev](https://blog.arazygroup.com/regulatory-affairs-advance/author/diana-gavrilov-negev) 

[Read More](https://blog.arazygroup.com/regulatory-affairs-advance/clinical-evaluation-reports)

[Follow us on Facebook](https://www.facebook.com/Arazygroup/) [Follow us on LinkedIn](https://www.linkedin.com/company/arazy-group) [Follow us on Instagram](https://www.instagram.com/arazy_group/)

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "Arazy Group",
    "url" : "https://blog.arazygroup.com/regulatory-affairs-advance/author/arazy-group"
  },
  "dateModified" : "2024-06-21T18:48:26.360Z",
  "datePublished" : "2023-10-12T19:58:36.000Z",
  "headline" : "Regulatory Update: Serbia",
  "image" : [ "https://blog.arazygroup.com/hubfs/imgpsh_fullsize_anim-Oct-12-2023-07-58-09-2825-PM.jpg" ],
  "mainEntityOfPage" : {
    "@id" : "https://blog.arazygroup.com/regulatory-affairs-advance/regulatory-update-serbia",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://blog.arazygroup.com/hubfs/Arazy%20Group%20Logos%201.png"
    },
    "name" : "Arazy Group Consultants Inc."
  }
}
```